他汀序贯治疗对择期PCI患者血清IMA及hs-CRP的影响

目的：探讨他汀序贯治疗对择期PCI患者血清缺血修饰清蛋白（IMA）和超敏C反应蛋白（hs-CRP）水平的影响。方法：选取择期PCI患者98例,随机分为常规他汀治疗组56例（阿托伐他汀20mg/d）和他汀序贯治疗组42例,观察PCI术前、术后12h两组血清IMA、hs-CRP水平的变化。结果：PCI术前及术后他汀序贯治疗组血清IMA、hs-CRP水平明显低于常规他汀治疗组,比较差异有统计学意义（P〈0.05）;与常规他汀治疗组比较,他汀序贯治疗组PCI术后6个月主要心血管事件发生率明显降低,比较差异有统计学意义（P〈0.05）。结论：他汀序贯治疗能显著改善择期PCI患者心肌损伤,对心肌起主要的保护作用,降低PCI术后主要心血管事件的发生,且安全有效。

Effects of Sequential Therapy of Atorvastatin on Levels of High Ischemia Modified Albumin and High Sensitivity C-reactive Protein in Patients Undergoing Elective Percutaneous Coronary Intervention

Objective： To investigate the effects of sequential therapy of atorvastatin on levels of high ischemia modified albumin and high sensitivity C-reactive protein in patients undergoing elective percutaneous coronary intervention.Method： Total 98 patients undergoing PCI were randomly divided into the routine treatment group of 56 cases （ atorvastatin 20 mg/d ） and the sequential therapy group of 42 cases.Observing changes on the serum levels of high ischemia modified albumin and high sensitivity C-reactive protein between the two groups PCI preoperative.Result： The serum level of IMA and hs-CRP was obviously lower in sequential therapy group than in routine treatment group after and before PCI （ P〈0.05 ） .Comparing to the routine treatment group, the MACE in sequential therapy group decreased with statistical significance （ P〈O.05 ） .Conclusion： Atorvastatin sequential treatment can reduce the elective PCI in patients with myocardial injury after PCI, reduced major adverse cardiac events, safe and effective.